Hong Lin1, Yuan-Ming Zhang2. 1. Heart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, China. 2. Heart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, China. Electronic address: zymdxx@163.com.
Abstract
AIMS: Evaluating the short-term influence of Ezetimibe and Simvastatin Combination Therapy on LDL-C, TG and hs-CRP expression level in patients with percutaneous coronary intervention. METHODS:57 cases of percutaneous coronary intervention patients were selected, and randomly divided into two groups: Simvastatin (40mg/day) and Ezetimibe (10mg/day) combination therapy group (observation group) with 28 patients, Simvastatin (40mg/day) group (control group) with 29 patients. Each group was treated for 10days. After treatment, compare blood lipid LDL-C, TG, hs-CRP levels with each other and the results before treatment. RESULTS: Comparison of the results of the 10th day with the baseline: LDL-C, TG decreased significantly (P<0.01) in the observation group, while the control group did not have a significantly change (P>0.05). Comparison of observation group and control group: after treatment, LDL-C and TG decreased more significantly in the observation group than the control group (-27.2% vs -14.6%, P<0.05). Whether according to LDL-C <2.07mmol/L standard or LDL-C <1.8mmol/L standard, the compliance rate of the observation group was significantly better than the control group, the results were (69% vs 28.9%, P<0.05) and (47.6% vs 13.2% P<0.05), respectively. After 10days treatment, comparing to baseline, hs-CRP was significantly lowered in these two groups (P<0.01). And there is no liver and kidney toxicity, myopathy and other adverse reactions during treatment. CONCLUSIONS: Combination therapy of Ezetimibe (10mg/day) and Simvastatin (40mg/day) was more effective than mono-therapy with Simvastatin (40mg/day) on reducing LDL-C, TG and hs-CRP level in percutaneous coronary intervention patients, leading to more significant anti-inflammatory effect.
RCT Entities:
AIMS: Evaluating the short-term influence of Ezetimibe and Simvastatin Combination Therapy on LDL-C, TG and hs-CRP expression level in patients with percutaneous coronary intervention. METHODS: 57 cases of percutaneous coronary intervention patients were selected, and randomly divided into two groups: Simvastatin (40mg/day) and Ezetimibe (10mg/day) combination therapy group (observation group) with 28 patients, Simvastatin (40mg/day) group (control group) with 29 patients. Each group was treated for 10days. After treatment, compare blood lipid LDL-C, TG, hs-CRP levels with each other and the results before treatment. RESULTS: Comparison of the results of the 10th day with the baseline: LDL-C, TG decreased significantly (P<0.01) in the observation group, while the control group did not have a significantly change (P>0.05). Comparison of observation group and control group: after treatment, LDL-C and TG decreased more significantly in the observation group than the control group (-27.2% vs -14.6%, P<0.05). Whether according to LDL-C <2.07mmol/L standard or LDL-C <1.8mmol/L standard, the compliance rate of the observation group was significantly better than the control group, the results were (69% vs 28.9%, P<0.05) and (47.6% vs 13.2% P<0.05), respectively. After 10days treatment, comparing to baseline, hs-CRP was significantly lowered in these two groups (P<0.01). And there is no liver and kidney toxicity, myopathy and other adverse reactions during treatment. CONCLUSIONS: Combination therapy of Ezetimibe (10mg/day) and Simvastatin (40mg/day) was more effective than mono-therapy with Simvastatin (40mg/day) on reducing LDL-C, TG and hs-CRP level in percutaneous coronary intervention patients, leading to more significant anti-inflammatory effect.